Lb Pharmaceuticals (LBRX) Non Operating Investment Income (2024 - 2025)
Lb Pharmaceuticals (LBRX) posted quarterly Non Operating Investment Income of $119000.0 for Q1 2025, down 67.13% quarter-over-quarter from $362000.0 in Q4 2024.
Powered by 
Analysis
Lb Pharmaceuticals (LBRX) Non Operating Investment Income (2024 - 2025) Analysis & Trends
Lb Pharmaceuticals' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $119000.0 for Q1 2025.
- In Q1 2025, Non Operating Investment Income changed N/A year-over-year to $119000.0; the TTM figure through Mar 2026 stood at $119000.0 (changed N/A YoY), while the FY2025 annual figure was $119000.0, down 87.54% from the prior year.
- Non Operating Investment Income for Q1 2025 stood at $119000.0, down from $362000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $503000.0 in Q3 2024, with the low at $119000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Lb Pharmaceuticals | 1.49 Bn | 1.49 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | 503,000.00 |